<DOC>
	<DOCNO>NCT01879345</DOCNO>
	<brief_summary>Single centre , double-blind , randomise , placebo-controlled study two dosage regimen BIA 2-093 - 1800 mg ( Group 1 ) 2400 mg ( Group 2 ) - two group healthy male volunteer</brief_summary>
	<brief_title>A Study Evaluate Tolerability Pharmacokinetics Two Single Multiple High Dose Regimens BIA 2-093 In Healthy Volunteers</brief_title>
	<detailed_description>Within group ( n=9 ) 3 volunteer randomise receive placebo remain 6 volunteer receive BIA 2-093 . No volunteer member one treatment group . In group , study consist single-dose period ( Phase A ) follow 7-day multiple-dose period ( Phase B ) . The multiple-dose phase start 96 h post single-dose . Progression 2400 mg dose ( Group 2 ) occur 1800 mg dose ( Group 1 ) consider safe well tolerate . An appropriate interval separate investigation two group order permit timely review evaluation safety data . Treatment consist single-dose ( Phase A ) follow once-daily dose 7 day ( Phase B ) . Doses prepared follow : Group 1 = 3 tablet BIA 2-093 600 mg plus 1 placebo tablet , 4 placebo tablet ; Group 2 = 4 tablet BIA 2-093 600 mg , 4 placebo tablet .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , neurological examination , 12lead ECG . Subjects clinical laboratory test within normal range screen admission . Subjects negative test HBsAg , antiHCV Ab HIV1 HIV2 Ab screen . Subjects negative drug abuse alcohol screen admission . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . Subjects conform inclusion criterion , OR Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects significant infection know inflammatory process screen admission . Subjects acute gastrointestinal symptom time screen admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use prescription overthecounter medication within 2 week admission . Subjects use investigational drug participate clinical trial within 3 month admission . Subjects previously receive BIA 2093 . Subjects donate received blood blood product within previous 3 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Anticonvulsant</keyword>
</DOC>